Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B

Journal of Hepatology

Volumn 47, Issue 2, 2007, Pages 191-202

  Hui, Chee Kin ^a   Zhang, Hai Ying ^a   Lee, Nikki P ^a   Chan, Weng ^a   Yueng, Yui Hung ^a   Leung, Kar Wai ^a   Lu, Lei ^a   Leung, Nancy ^b   Lo, Chung Mau ^a   Fan, Sheung Tat ^a   Luk, John M ^a   Xu, Aimin ^a   Lam, Karen S ^a   Kwong, Yok Lam ^a   Lau, George K K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

Author keywords

Adiponectin; Adiponectin oligomeric form; Chronic hepatitis B; Lamivudine; Liver cirrhosis; Pegylated interferon alfa 2a; Sustained virological response

Indexed keywords

ADIPONECTIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MONOTHERAPY; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COHORT STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX;

EID: 34347389866     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.02.023     Document Type: Article

References (32)

1. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24 (2004) 29-33
2. Tschritter O., Fritsche A., Thamer C., Haap M., Shirkavand F., Rahe S., et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52 (2003) 239-243
3. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
4. Tacke F., Wustefeld T., Horn R., Luedde T., Srinivas Rao A., Manns M.P., et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 42 (2005) 666-673
5. Kamada Y., Tamura S., Kiso S., Matsumoto H., Saji Y., Yoshida Y., et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125 (2003) 1796-1807
6. Tietge U.J., Boker K.H., Manns M.P., and Bahr M.J. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 287 (2004) E82-E89
7. Jonsson J.R., Moschen A.R., Hickman I.J., Ricardson M.M., Kaser S., Clouston A.D., et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 43 (2005) 929-936
8. Liu C.J., Chen P.J., Jeng Y.M., Huang W.L., Yang W.S., Lai M.Y., et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 43 (2005) 235-242
9. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat T., Cooksley G., et al. Peginterferon alfa-2a (40 kDa) (PEGASYS) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg positive chronic hepatitis B: results from a large, multinational study. N Eng J Med 352 (2005) 2682-2695
10. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001) 421-430
11. Hui C.K., Lie A., Au W.Y., Leung Y.H., Ma S.Y., Cheung W.W., et al. A long-term follow-up study on hepatitis B surface antigen positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 106 (2005) 464-469
12. Hui C.K., Lau E., Monto A., Kim M., Luk J.M., Poon R.T., et al. Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation. Am J Transplant 6 (2006) 1600-1608
13. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med 15 (2004) 539-553
14. Ishak K.G., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
15. Xu A., Chan K.W., Hoo R.L., Wang Y., Tan K.C., Zhang J., et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280 (2005) 18073-18080
16. Corbetta S., Bulfamante G., Cortelazzi D., Barresi I., Mantovani G., Bondioni S., et al. Adiponectin expression in human fetal tissues during mid- and late gestation. J Clin Endocrinol Metab 90 (2005) 2397-2402
17. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131 (2006) 59-68
18. Lau G.K., Leung Y.H., Fong D.Y., Au W.Y., Kwong Y.L., Lie A., et al. High hepatitis B virus (HBV) DNA as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99 (2002) 2324-2330
19. Hui C.K., Lai L., Lam P., Zhang H.Y., Fung T.T., Wong W.M., et al. 48 weeks pegylated interferon alfa-2a is superior to 24 weeks of pegylated interferon alfa-2b in achieving HBeAg seroconversion in chronic hepatitis B infection. Aliment Pharmacol Ther 23 (2006) 1171-1178
20. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26 (2005) 439-451
21. Diez J.J., and Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148 (2003) 293-300
22. Kaser S., Moschen A., Kaser A., Ludwiczek O., Ebenbichler C.F., Vogel W., et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 258 (2005) 274-280
23. Sohara N., Takagi H., Kakizaki S., Sato K., and Mori M. Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels. Liver Int 25 (2005) 28-32
24. Kobayashi H., Ouchi N., Kihara S., Walsh K., Kumada M., Abe Y., et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94 (2004) e27-e31
25. Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., Wagner J.A., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279 (2004) 12152-12162
26. Wang Y., Lam K.S., Xu J.Y., Lu G., Xu L.Y., Cooper G.J., et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280 (2005) 18341-18347
27. Tsao T.S., Murrey H.E., Hug C., Lee D.H., and Lodish H.F. Oligomerization state-dependent activation of NF-κB signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 277 (2002) 29359-29362
28. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W., Goodman Z., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Eng J Med 341 (1999) 1256-1263
29. Lau G.K., Cooksley G., Marcellin P., Piratvisuth T., Hadziyannis S., Dunant H., et al. Predictors of histologic improvement and relationship between sustained response and histology in patients with HBeAg positive and HBeAg netaive chronic hepatitis B treated with Peginterferon alpha 2a (40 kDa)(PEGASYS). Hepatology 42 (2005) 587A
30. Liaw Y.F., Sung J.J., Chow W.C., Farrell G.C., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
31. Wu P.C., Lok A.S., Lau J.Y., Lauder I.J., and Lai C.L. Histologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-α therapy. Am J Clin Pathol 98 (1992) 402-407
32. Hadziyannis S., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Eng J Med 352 (2005) 2673-2681